Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal China Sell-Off Deal Advances

Executive Summary

The potential acquisition of Cardinal Health’s China business by Shanghai Pharmaceuticals could have significant strategic implications for the state-owned suitor, but it’s probably still “hard to assume” how the transaction may finally pan out. Expectations around the deal value are still in excess of $1bn, investor sources tell Scrip.

You may also be interested in...



Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration

The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.

Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals

Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.

2017 Preview: Fresh Concerns And New Hopes In China

If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.

Topics

Related Companies

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel